Drive novel cancer diagnostic and therapeutic development through identification of microbial targets
For pharma, biotech, and academic institutions looking to identify, validate, and commercialize microbiome-based data in cancer care, MicrobiomeDX helps lead discovery efforts in investigating microbial targets for diagnostic and therapeutic applications.
Identify therapeutic response indicators and gut health microbial markers in cancer research
For pharma, biotech, clinical, and academic clients exploring patients’ and cohorts’ microbiome profiles for pre- and clinical studies. MicrobiomeDX is a CLIA lab delivering data-generation and analyses using our BacProTM pipeline built by leading cancer and microbiome experts.